SNGX
Soligenix, Inc. [SNGX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SNGX Stock Summary
Top 10 Correlated ETFs
SNGX
Top 10 Correlated Stocks
SNGX
In the News
SNGX Financial details
SNGX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.58 | 1.29 | 0.31 | 0.33 | 0.11 | |
| Net income per share | -7.24 | -9.65 | -4.69 | -4.81 | -0.79 | |
| Operating cash flow per share | -5.81 | -6.25 | -4.39 | -4.41 | -1.11 | |
| Free cash flow per share | -5.84 | -6.25 | -4.39 | -4.41 | -1.11 | |
| Cash per share | 4.2 | 10.19 | 9.73 | 4.65 | 1.09 | |
| Book value per share | 1.13 | 2.04 | 4.01 | -0.86 | 0.33 | |
| Tangible book value per share | 1.11 | 2.03 | 4 | -0.86 | 0.33 | |
| Share holders equity per share | 1.13 | 2.04 | 4.01 | -0.86 | 0.33 | |
| Interest debt per share | 0.1 | 5.74 | 4.05 | 3.85 | 0.44 | |
| Market cap | 28.1M | 35.18M | 26.49M | 19.38M | 5.87M | |
| Enterprise value | 22.8M | 27.01M | 10.41M | 16.26M | 922.79K | |
| P/E ratio | -3 | -1.99 | -2.11 | -1.4 | -0.96 | |
| Price to sales ratio | 6.07 | 14.91 | 32.13 | 20.42 | 7 | |
| POCF ratio | -3.74 | -3.07 | -2.26 | -1.53 | -0.68 | |
| PFCF ratio | -3.73 | -3.07 | -2.25 | -1.53 | -0.68 | |
| P/B Ratio | 19.28 | 9.4 | 2.47 | -7.84 | 2.33 | |
| PTB ratio | 19.28 | 9.4 | 2.47 | -7.84 | 2.33 | |
| EV to sales | 4.93 | 11.45 | 12.62 | 17.14 | 1.1 | |
| Enterprise value over EBITDA | -2.27 | -1.47 | -0.81 | -1.16 | -0.11 | |
| EV to operating cash flow | -3.04 | -2.36 | -0.89 | -1.29 | -0.11 | |
| EV to free cash flow | -3.02 | -2.36 | -0.89 | -1.28 | -0.11 | |
| Earnings yield | -0.33 | -0.5 | -0.47 | -0.71 | -1.05 | |
| Free cash flow yield | -0.27 | -0.33 | -0.44 | -0.65 | -1.46 | |
| Debt to equity | 0.09 | 2.81 | 0.93 | -4.14 | 1.34 | |
| Debt to assets | 0.02 | 0.53 | 0.37 | 0.72 | 0.35 | |
| Net debt to EBITDA | 0.53 | 0.44 | 1.25 | 0.22 | 0.59 | |
| Current ratio | 1.19 | 3.2 | 4.22 | 0.84 | 1.55 | |
| Interest coverage | 0 | -1.7K | -15.03 | -17.15 | -173.77 | |
| Income quality | 0.8 | 0.65 | 0.94 | 0.92 | 1.4 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.75 | 1.69 | 5.88 | 7.05 | 5.34 | |
| Research and developement to revenue | 1.75 | 6.42 | 10.18 | 8.37 | 3.94 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | 0 | -0.01 | -0.01 | 0 | |
| Capex to depreciation | -0.55 | -0.11 | -0.35 | -0.53 | 0 | |
| Stock based compensation to revenue | 0.08 | 0.17 | 0.44 | 0.35 | 0.44 | |
| Graham number | 13.56 | 21.06 | 20.57 | 9.65 | 2.41 | |
| ROIC | -5.54 | -1.22 | -0.58 | -1.6 | -1.1 | |
| Return on tangible assets | -1.21 | -0.89 | -0.47 | -0.97 | -0.63 | |
| Graham Net | 0.15 | 1.61 | 3.77 | -1.12 | 0.17 | |
| Working capital | 1.18M | 13.39M | 20.28M | -2.66M | 3.36M | |
| Tangible asset value | 1.44M | 3.72M | 10.71M | -2.47M | 2.52M | |
| Net current asset value | 1.18M | 3.32M | 10.42M | -2.9M | 2.23M | |
| Invested capital | 0.09 | 2.81 | 0.93 | -4.14 | 1.34 | |
| Average receivables | 1.33M | 1.01M | 403.8K | 231.02K | 207.24K | |
| Average payables | 2.43M | 2.43M | 2.53M | 3.4M | 2.49M | |
| Average inventory | 1 | 1 | 0 | 0.5 | 0.5 | |
| Days sales outstanding | 115.33 | 87.38 | 107.48 | 84.36 | 84.86 | |
| Days payables outstanding | 279.88 | 426.92 | 1.47K | 2.56K | 541.81 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.16 | 4.18 | 3.4 | 4.33 | 4.3 | |
| Payables turnover | 1.3 | 0.85 | 0.25 | 0.14 | 0.67 | |
| Inventory turnover | 1.78M | 0 | 0 | 550.82K | 0 | |
| ROE | -6.42 | -4.73 | -1.17 | 5.58 | -2.43 | |
| Capex per share | -0.02 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.13 | 0.09 | 0.03 | 0.01 | 0.02 | |
| Net income per share | -1.7 | -0.36 | -0.22 | -0.16 | -0.18 | |
| Operating cash flow per share | -1.26 | -0.74 | -0.27 | -0.26 | -0.18 | |
| Free cash flow per share | -1.25 | -0.74 | -0.27 | -0.26 | -0.18 | |
| Cash per share | 4.63 | 3.52 | 1.82 | 0.99 | 0.81 | |
| Book value per share | -0.86 | -1.16 | 0.8 | 0.41 | 0.24 | |
| Tangible book value per share | -0.86 | -1.16 | 0.8 | 0.41 | 0.24 | |
| Share holders equity per share | -0.86 | -1.16 | 0.8 | 0.41 | 0.24 | |
| Interest debt per share | 3.61 | 3.13 | 0.44 | 0.31 | 0.33 | |
| Market cap | 19.46M | 5.74M | 5.07M | 5.79M | 7.86M | |
| Enterprise value | 16.34M | 4.7M | -4.95M | -1.33M | 2.91M | |
| P/E ratio | -0.99 | -1.37 | -0.79 | -0.87 | -1.08 | |
| Price to sales ratio | 53.16 | 22.33 | 24.51 | 44.36 | 32.1 | |
| POCF ratio | -5.36 | -2.65 | -2.64 | -2.15 | -4.3 | |
| PFCF ratio | -5.38 | -2.65 | -2.64 | -2.15 | -4.3 | |
| P/B Ratio | -7.88 | -1.7 | 0.87 | 1.37 | 3.12 | |
| PTB ratio | -7.88 | -1.7 | 0.87 | 1.37 | 3.12 | |
| EV to sales | 44.64 | 18.28 | -23.94 | -10.22 | 11.87 | |
| Enterprise value over EBITDA | -4.58 | -2.19 | 3.06 | 0.73 | -1.24 | |
| EV to operating cash flow | -4.5 | -2.17 | 2.58 | 0.5 | -1.59 | |
| EV to free cash flow | -4.52 | -2.17 | 2.58 | 0.5 | -1.59 | |
| Earnings yield | -0.25 | -0.18 | -0.32 | -0.29 | -0.23 | |
| Free cash flow yield | -0.19 | -0.38 | -0.38 | -0.46 | -0.23 | |
| Debt to equity | -4.14 | -2.72 | 0.54 | 0.75 | 1.34 | |
| Debt to assets | 0.72 | 0.83 | 0.23 | 0.28 | 0.35 | |
| Net debt to EBITDA | 0.87 | 0.49 | 6.19 | 3.92 | 2.1 | |
| Current ratio | 0.84 | 0.94 | 2.34 | 1.99 | 1.55 | |
| Interest coverage | -19.76 | 20.7 | -27.08 | -26.81 | 0 | |
| Income quality | 0.97 | 2.07 | 1.19 | 1.62 | 1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.94 | 4.8 | 4.3 | 7.46 | 5.65 | |
| Research and developement to revenue | 6.44 | 3.68 | 3.69 | 6.33 | 3.17 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0.04 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 4.32 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.31 | 0.29 | 0.44 | 0.5 | 0.58 | |
| Graham number | 5.73 | 3.06 | 2 | 1.21 | 0.98 | |
| ROIC | -0.58 | -0.17 | -0.18 | -0.22 | -0.3 | |
| Return on tangible assets | -0.34 | -0.09 | -0.12 | -0.15 | -0.19 | |
| Graham Net | -1.12 | -1.39 | 0.72 | 0.32 | 0.13 | |
| Working capital | -2.66M | -654.73K | 7.71M | 5.45M | 3.36M | |
| Tangible asset value | -2.47M | -3.39M | 5.8M | 4.22M | 2.52M | |
| Net current asset value | -2.9M | -3.77M | 5.45M | 3.89M | 2.23M | |
| Invested capital | -4.14 | -2.72 | 0.54 | 0.75 | 1.34 | |
| Average receivables | 225.22K | 231.06K | 190.91K | 113.97K | 142.03K | |
| Average payables | 4.02M | 3.32M | 2.62M | 1.97M | 1.29M | |
| Average inventory | 1 | 1 | 1 | 0.5 | 0 | |
| Days sales outstanding | 53.92 | 84.96 | 60.47 | 61.34 | 71.74 | |
| Days payables outstanding | 2.56K | 1.1K | 1.21K | 1.19K | 448.2 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.67 | 1.06 | 1.49 | 1.47 | 1.25 | |
| Payables turnover | 0.04 | 0.08 | 0.07 | 0.08 | 0.2 | |
| Inventory turnover | 135.87K | 226.04K | 184.02K | 0 | 0 | |
| ROE | 1.99 | 0.31 | -0.28 | -0.39 | -0.72 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SNGX Frequently Asked Questions
What is Soligenix, Inc. stock symbol ?
Soligenix, Inc. is a US stock , located in Princeton of Nj and trading under the symbol SNGX
What is Soligenix, Inc. stock quote today ?
Soligenix, Inc. stock price is $0.4999 today.
Is Soligenix, Inc. stock public?
Yes, Soligenix, Inc. is a publicly traded company.
Company Profile
- Volume Average 164.08K
- Market Capitalization 4.06M
- Employee 13
- CEO Dr. Christopher J. Schaber Ph.D.
- Headquarters Princeton,NJ,US
- IPO Date 1994-04-04
-
Website
https://www.soligenix.com 
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
